This year’s BIO international Convention is back in Boston again after 5 years in other cities or going digital during the pandemic.
Considering the number of attendees (at least 18,000 from 85 countries) and exhibiting companies in a fully packed exhibition area, it feels like BIO in Boston 2018, yet significantly different in some respects. The program sessions comprise the full spectrum of topics from Cell and Gene Therapy and Genome editing, Next Generation Biotherapeutics, Personalized Medicine, Manufacturing, Regulatory and Business Development & Finance through to the various disease areas. The exhibition is huge as usual.
What stands out are big pavilions housing CDMO companies from all over the world alongside smaller companies offering other services – and then of course all the country- and regional pavilions.
A total of 155 companies from the Nordics were attending, 67 from Sweden, 46 from Denmark, 23 from Finland, 15 from Norway and 4 companies from Iceland.
I am looking forward to the rest of the conference!
Stay updated on nordilifescience.org for more BIO updates from Ola Björkman and a longer summary focusing on Nordic participation and impact!